Susquehanna International Group’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.8M Sell
567,500
-895,800
-61% -$14.5M ﹤0.01% 3011
2025
Q4
$25.6M Buy
1,463,300
+244,800
+20% +$4.61M ﹤0.01% 1958
2025
Q3
$25.2M Buy
1,218,500
+139,300
+13% +$3.38M ﹤0.01% 1960
2025
Q2
$23M Buy
1,079,200
+504,400
+88% +$11.5M ﹤0.01% 1864
2025
Q1
$11.1M Buy
574,800
+181,700
+46% +$3.65M ﹤0.01% 2395
2024
Q4
$7.02M Sell
393,100
-92,100
-19% -$1.79M ﹤0.01% 3101
2024
Q3
$10.6M Buy
485,200
+157,000
+48% +$2.2M ﹤0.01% 2539
2024
Q2
$2.56M Buy
328,200
+248,700
+313% +$1.34M ﹤0.01% 4605
2024
Q1
$329K Buy
79,500
+32,400
+69% +$129K ﹤0.01% 9503
2023
Q4
$123K Sell
47,100
-535,100
-92% -$1.1M ﹤0.01% 11161
2023
Q3
$1.09M Buy
582,200
+521,900
+866% +$995K ﹤0.01% 6444
2023
Q2
$151K Sell
60,300
-101,700
-63% -$186K ﹤0.01% 10565
2023
Q1
$284K Sell
162,000
-406,900
-72% -$1.11M ﹤0.01% 9844
2022
Q4
$2.42M Buy
+568,900
New +$1.03M ﹤0.01% 4382
2022
Q1
Sell
-24,300
Closed -$65K 13895
2021
Q4
$65K Sell
24,300
-43,100
-64% -$207K ﹤0.01% 12420
2021
Q3
$338K Sell
67,400
-39,900
-37% -$286K ﹤0.01% 10319
2021
Q2
$800K Buy
+107,300
New +$704K ﹤0.01% 8377

Other funds holding SMMT

Susquehanna International Group's SMMT Position: Q1 2026 in Review

Susquehanna International Group opened a new position in Summit Therapeutics (SMMT) in Q1 2026: 603,933 shares worth $11.5M. The stake represents ﹤0.01% of the portfolio and ranks #2909 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in SMMT as recently as Q3 2025.

Susquehanna International Group first reported a position in SMMT in Q3 2017 and has held it in 22 quarters since. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Susquehanna International Group held 603,933 shares of Summit Therapeutics worth $11.5M as of Q1 2026.
  • Summit Therapeutics was a new Susquehanna International Group position in Q1 2026.
  • Summit Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2909 holding.
  • Susquehanna International Group first reported a position in Summit Therapeutics in Q3 2017 and has held it in 22 quarters since.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.